Results

Total Results: 1,524 records

Showing results for "drugs".

201. Restless-Legs Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/restless-legs_executive.pdf
     November 01, 2012 - Pharmacologic interventions included drugs approved for use (for any condition) in the United States … Pharmacologic interventions were limited to drugs approved for use (for any condition) in the United … We assessed statistical heterogeneity between trials and for subgroups of drugs using the I2 test and … The drugs did not differ with regard to any study withdrawals. … Augmentation, a drug-induced exacerbation of the disease, can occur with dopaminergic drugs.

202. DEcIDE 33: Summary Variables in Observational Resesarch: Propensity Scores and Disease Risk Scores (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/observational-research-scores_research.pdf
     May 01, 2012 - All dispensings of the two drugs were identified, and subjects who received glimepiride who did not … In this example, we assume that there are nine individual drugs of interest, six traditional NSAIDs … Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. … COX-2 selective non-steroidal anti- inflammatory drugs and risk of serious coronary heart disease. … Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

203. VU EPC DBD Protocol_AHRQ comments_revised_clean (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/disruptive-behavior-disorder_research-protocol.pdf
     January 30, 2014 - CNS Drugs. 2006;20(7):549-65. PMID: 16800715 41. Newcorn JH, Ivanov I. … BTA Pharmaceuticals Inc., Bridgewater, NJ Bupropion Mylan Pharmaceuticals Inc., Morgantown, WV Selective … New York, NY Citalopram Teva Pharmaceuticals, Sellersville, PA Escitalopram Teva Pharmaceuticals, Sellersville … , PA Paroxetine Teva Pharmaceuticals, Sellersville, PA Fluvoxamine Mylan Pharmaceuticals Inc., Morgantown … ") OR SU.EXACT.EXPLODE("Adrenergic Drugs")) OR (SU.EXACT.EXPLODE("Anticonvulsive Drugs") OR SU.EXACT.EXPLODE

204. Long-Term Drug Therapy and Drug Holidays for Osteoporotic Fracture Prevention (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/research-protocol-osteoporosis_2.pdf
     October 05, 2018 - Drugs Used for Osteoporosis Treatment and Prevention Drug class Drug name Delivery route Dosing … Interventions • Drugs FDA approved for osteoporosis treatment or prevention (bisphosphonates, denosumab

205. Slide 1
     effectivehealthcare.ahrq.gov/sites/default/files/comparator-selection-in-observational-chapter-5.pptx
     January 01, 2013 - Example: When comparing the adverse metabolic effects of antipsychotic drugs, body mass index is a potential … study assessing the risk of cancer in statin users, an active comparator group of patients on glaucoma drugs … Although device or drug registries may provide detailed data on the use of drugs, biologics, and devices … Different Treatment Modalities (1 of 3) Confounding by Indication or Severity For some conditions, drugs … Adherence to Drugs and Device Failure or Removal Patients who are on medications could have various degrees

206. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/renal-artery-stenosis_executive.pdf
     October 01, 2006 - comparing angioplasty with stent placement and “aggressive” medical treatment with currently available drugs … after revascularization do occur in a small percentage of patients, and each of the antihypertensive drugs … blood pressure generally decreased by 20-50/8-42 mm Hg with combinations of multiple antihypertensive drugs … eligibility criteria reported analyses of whether other periprocedural interventions, such as different drugs … eligibility criteria reported analyses of whether other periprocedural interventions, such as different drugs

207. Disposition of Comments Report for CER 132 Combination Therapy Versus Intensification of Statin Monotherapy: An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medicines-update_disposition-comments.pdf
     September 01, 2014 - In fact, after reading the Introduction and all of the difficulties in evaluating these alternate drugs … In some ways there is more harm in adding these drugs as compared to raising the dose of the statins … The relative efficacy and dose ranges for individual statin drugs is shown in Table 4 of the report … Finally, as the report notes there is little to no evidence that adding these alternative drugs to … Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

208. Disposition of Comments: CER 228, Nonopioid Pharmacologic Treatments for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-228-nonopioid-pharm-chronic-pain-comments.pdf
     April 16, 2020 - of 4 will addict, then there would be ~25 million Americans addicted, and actively seeking illicit drugs … This was a 13-week randomized trial comparing escitalopram with duloxetine and showed that both drugs … Each of the pharmaceuticals studied have unique profiles that make them clinically appropriate for … ASRA recognizes that all drugs – opioid and nonopioid – carry risks. … This report examines the evidence-base for nonopioid drugs used to treat chronic pain, varying by pain

209. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1406.pdf
     June 01, 2014 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Results The table below lists the two topics for which (1) preliminary phase III data on drugs, phase … A third topic that was in the December 2013 report, the oral tablet ivacaftor (Kalydeco™, Vertex Pharmaceuticals

210. Medical Care Journal Supplement (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/toc.pdf
     January 01, 2007 - Assessment of Adherence to and Persistence on Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Patients … Comparison of Meta-Analytic Results of Indirect, Direct, and Combined Comparisons of Drugs for Chronic

211. Disposition of Comments for CER 159 Insomnia (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/insomnia_disposition-comments.pdf
     December 30, 2015 - We did not identify eligible trials of antihistaminergic drugs or alcohol. … We have added text describe how specific drugs or formulations can be used to target specific sleep … problems (Introduction: ‘Drugs can be specifically formulated…’). … One of the most commonly used drugs for insomnia. No evidence. … Drugs Aging. 2014 Oct;31(10):731-6. doi: 10.1007/s40266-014-0211-3.

212. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1306.pdf
     January 01, 2016 - San Diego (CA): Amylin Pharmaceuticals, Inc.; 2010 Jun 15 [accessed 2011 Feb 22]. [3 p]. … Amylin Pharmaceuticals. … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27 [accessed 2012 Feb 20]. [4 p]. … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27. 11 p. … Get drugs straight to the eye. [internet].

213. Insomnia Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/insomnia_executive.pdf
     December 01, 2015 - Prescription drugs are often used to treat insomnia. … We found the most data on the newer FDA-approved drugs. … Results for adverse effects varied across the different drugs and typically were not different from … Drug trials for certain drugs often used doses that are no longer recommended by the FDA. … Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2 [Internet].

214. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/infectiousdisease_hi_impact.pdf
     December 01, 2013 - Telaprevir Telaprevir (Incivek™, Vertex Pharmaceuticals, Inc., Cambridge, MA) is orally administered … Optimer Pharmaceuticals announced a 2-year agreement with Cubist Pharmaceuticals, Inc. … Tibotec Pharmaceuticals, Vertex Pharmaceuticals. … Berlin: Vertex Pharmaceuticals; 2011 Mar 31 [accessed 2011 May 17]. [4 p]. … (FDA briefing document for Anti-Infective Drugs Advisory committee meeting).

215. S149 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s149.pdf
     October 01, 2007 - longitudinal pro- pensity score to compare outcomes between a new drug (exenatide) and established drugs … We used our methods to estimate the effect of the new versus established drugs on total health care charges … Additionally, a separate, linkable file is available which includes pharmacy claims for prescription drugs … May 2005 14,052 0.00 0.46 0.45 Emergency room visit June 2005 36 0.00 0.47 0.49 No. drugs June 2005 … This methodology has particular value for the study of new drugs.

216. Treatment of Dementia Among Community-Dwelling and Institutionalized Medicare Beneficiaries (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dementia-databases-methods_research.pdf
     May 01, 2008 - Use of anti-dementia drugs was similar across settings, with 24.7% of dementia cases in the community … larger than in the community, but there is little difference in the proportions receiving anti-dementia drugs … In a previous study, the authors13 reviewed 81 recent randomized clinical trials of dementia drugs … Our analysis of drugs typically used to treat behavioral manifestations of dementia found that treatment … these utilization rates are not adjusted for potential confounding factors, we cannot conclude the drugs

217. PROPOSALS FOR A PHASED EVALUATION OF (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/medical-tests-proposals_research.pdf
     January 01, 2009 - Background—In drug development, a four-phase hierarchical model for the clinical evaluation of new pharmaceuticals … Analogous to the four-phase model for the evaluation of new drugs, these models require that certain … Why have the phases in the clinical evaluation of drugs become so well engrained in our thinking, and … The four phases in the development of drugs and devices have shown their merit. … Trials in humans take place only after drugs have been tested thoroughly in the laboratory in animal

218. PROPOSALS FOR A PHASED EVALUATION OF (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/whitepaper3-lijmer02262010-2.pdf
     January 01, 2009 - Background—In drug development, a four-phase hierarchical model for the clinical evaluation of new pharmaceuticals … Analogous to the four-phase model for the evaluation of new drugs, these models require that certain … Why have the phases in the clinical evaluation of drugs become so well engrained in our thinking, and … The four phases in the development of drugs and devices have shown their merit. … Trials in humans take place only after drugs have been tested thoroughly in the laboratory in animal

219. CER 218 Disposition of Comments: Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-disposition-comments.pdf
     April 23, 2019 - Table 5) Comment: Table 4 defines the interventions to be included in this systematic review as “Drugs … to determine whether these harms were associated with long-term treatment with these osteoporosis drugs … Class-Specific Harms of Drugs Used for Osteoporosis Treatment has several important errors. … to determine whether these harms were associated with long-term treatment with these osteoporosis drugs … Results Public Commenter #1 (Rafael Pirtillo Ferman -Altietus College) Drugs still working Thank

220. 08 Functional Limitations Potential High Impact 2012-12-10 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/08_functional_limitations_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - Drugs Today 2010;46(1):49-67. 3. Sorbera LA, Dulsat C, Rosa E. … East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2011 Jul. 21 p. … Drugs Future 2010;35(2):93-7. … Drugs Today (Barc) 2010 Nov;46(11):815-22. PMID: 21225020 30. … Mountain View (CA): MAP Pharmaceuticals, Inc.; [accessed 2011 Jan 6]. [1 p].